The serotonin theory of depression: a systematic review of the evidence (2022)

Original Article ↗ Hacker News Discussion ↗

Serotonin theory vs. SSRIs

  • Commenters distinguish the “serotonin theory/hypothesis of depression” from the clinical question of whether SSRIs help.
  • Many note the field has long known that “low serotonin causes depression” is oversimplified and not well supported by evidence, even as SSRIs can still be useful drugs.
  • Some argue over semantics of “theory” vs “hypothesis” but others see this as a distraction from the substantive issues.

How SSRIs work (and what we don’t know)

  • Repeated emphasis that neurotransmitters are not simple “levels”; SSRIs change timing, receptor sensitivity (e.g., 5‑HT1A autoreceptor downregulation), and network dynamics over weeks.
  • Several note the delayed clinical effect despite rapid serotonin changes, arguing this alone disproves the “nutritional deficit” story.
  • Broader point: neuropsychopharmacology is extremely complex (many receptor subtypes, neuromodulation, cross‑talk between systems), so naive “happy chemical” narratives are misleading but popular (including in drug advertising).

Efficacy, placebo, and measurement problems

  • Strong disagreement about how well SSRIs work.
  • One camp stresses small average effect sizes and marginal advantage over placebo, especially in better‑blinded or active‑placebo trials, plus publication bias.
  • Another camp counters that:
    • Placebo itself performs unusually well in depression.
    • Some patients show large benefits even if averages are small.
    • Effect sizes for SSRIs are in the same ballpark as widely used drugs like morphine for pain.
  • Challenges highlighted: subjective outcome measures, strong expectancy/placebo effects, lack of “no‑treatment” controls, and heterogeneity of “depression” as a category.

Side effects, withdrawal, and overuse

  • Sexual dysfunction (sometimes persistent), emotional blunting, and possible weight gain are major concerns; some report life‑altering harms, others report manageable or transient issues.
  • Withdrawal can be severe; slow tapering is strongly recommended.
  • Many think SSRIs are over‑prescribed and often used as first‑line tools because they’re cheap and scalable, while therapy and other supports are less accessible.

Alternatives, complements, and broader framings

  • Multiple comments advocate combining SSRIs with psychotherapy, or prioritizing exercise, sleep, sunlight, weight loss, social and “meaning” interventions, and addressing trauma or social context.
  • Other pharmacologic options mentioned: bupropion, stimulants, MAOIs/tricyclics, ketamine, TMS/ECT, GLP‑1 agonists.
  • There are anecdotal reports of benefit from 5‑HTP and other supplements, alongside cautions about serotonin syndrome and self‑experimentation.
  • Several stress sociological and life‑context understandings of depression as more helpful than purely biological models.